General Information of Drug (ID: DMHBN8X)

Drug Name
60P002 Drug Info
Indication
Disease Entry ICD 11 Status REF
Dengue 1D20-1D2Z Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMHBN8X

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Platelet-activating factor receptor (PTAFR) TTQL5VC PTAFR_HUMAN Antagonist [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Platelet-activating factor receptor (PTAFR) DTT PTAFR 6.345 5.947 6.084 6.253
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Dengue
ICD Disease Classification 1D20-1D2Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Platelet-activating factor receptor (PTAFR) DTT PTAFR 3.53E-02 0.33 2.12
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02569827) Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of 60 Degrees Pharmaceuticals.